Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck

被引：85

作者：

Thomson, David J. ^{[1
]}

Silva, Priyamal ^{[2
]}

Denton, Kim ^{[1
]}

Bonington, Suzanne ^{[3
]}

Mak, Soo K. ^{[3
]}

Swindell, Ric ^{[4
]}

Homer, Jarrod ^{[2
]}

Sykes, Andrew J. ^{[1
]}

Lee, Lip W. ^{[1
]}

Yap, Beng K. ^{[1
]}

Slevin, Nicholas J. ^{[1
]}

机构：

[1] Christie NHS Fdn Trust, Dept Clin Oncol, Manchester M20 4BX, Lancs, England

[2] Christie NHS Fdn Trust, Dept Surg, Manchester M20 4BX, Lancs, England

[3] Christie NHS Fdn Trust, Dept Radiol, Manchester M20 4BX, Lancs, England

[4] Christie NHS Fdn Trust, Dept Med Stat, Manchester M20 4BX, Lancs, England

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2015年 / 37卷 / 02期

关键词：

trial; sorafenib; adenoid cystic carcinoma; ENDOTHELIAL-GROWTH-FACTOR; C-KIT; GLAND CARCINOMA; RECURRENT; CHEMOTHERAPY; BAY-43-9006; EXPRESSION; IMATINIB; CRITERIA; THERAPY;

D O I：

10.1002/hed.23577

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundThere is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease. MethodsIn a single-arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid. ResultsTwenty-three patients, median age 51 years, were recruited from 2009 to 2011. Median progression-free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity. ConclusionSorafenib showed modest activity in ACC with a 12-month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation. (c) 2014 Wiley Periodicals, Inc. Head Neck37: 182-187, 2015

引用

页码：182 / 187

页数：6

共 29 条

[1] Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands [J].

Agulnik, Mark ;

Cohen, Ezra W. E. ;

Cohen, Roger B. ;

Chen, Eric X. ;

Vokes, Everett E. ;

Hotte, Sebastien J. ;

Winquist, Eric ;

Laurie, Scott ;

Hayes, D. Neil ;

Dancey, Janet E. ;

Brown, Shirley ;

Pond, Gregory R. ;

Lorimer, Ian ;

Daneshmand, Manijeh ;

Ho, James ;

Tsao, Ming-Sound ;

Siu, Lillian L. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3978-3984

[2] A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck A Trial of the Eastern Cooperative Oncology Group (E1303) [J].

Argiris, Athanassios ;

Ghebremichael, Musie ;

Burtness, Barbara ;

Axelrod, Rita S. ;

Deconti, Ronald C. ;

Forastiere, Arlene A. .

CANCER, 2011, 117 (15) :3374-3382

[3] Salivary gland carcinoma in Denmark 1990-2005: A national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA) [J].

Bjorndal, Kristine ;

Krogdahl, Annelise ;

Therkildsen, Marianne Hamilton ;

Overgaard, Jens ;

Johansen, Jorgen ;

Kristensen, Claus A. ;

Homoe, Preben ;

Sorensen, Christian Hjort ;

Andersen, Elo ;

Bundgaard, Troels ;

Primdahl, Hanne ;

Lambertsen, Karin ;

Andersen, Lisbeth Juhler ;

Godballe, Christian .

ORAL ONCOLOGY, 2011, 47 (07) :677-682

[4]

Bradley Patrick J, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P127, DOI 10.1097/00020840-200404000-00013

[5] A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC [J].

Chau, N. G. ;

Hotte, S. J. ;

Chen, E. X. ;

Chin, S. F. ;

Turner, S. ;

Wang, L. ;

Siu, L. L. .

ANNALS OF ONCOLOGY, 2012, 23 (06) :1562-1570

[6] Selected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumors [J].

Dal Lago, Lissandra ;

D'Hondt, Veronique ;

Awada, Ahmad .

ONCOLOGIST, 2008, 13 (08) :845-858

[7] Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: Case report and review of literature [J].

Dammrich D.J. ;

Santos E.S. ;

Raez L.E. .

Journal of Medical Case Reports, 5 (1)

[8] Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies [J].

Dodd, R. L. ;

Slevin, N. J. .

ORAL ONCOLOGY, 2006, 42 (08) :759-769

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] Adenoid cystic carcinoma of the head and neck [J].

Ellington, Christopher L. ;

Goodman, Michael ;

Kono, Scott A. ;

Grist, William ;

Wadsworth, Trad ;

Chen, Amy Y. ;

Owonikoko, Taofeek ;

Ramalingam, Suresh ;

Shin, Dong M. ;

Khuri, Fadlo R. ;

Beitler, Jonathan J. ;

Saba, Nabil F. .

CANCER, 2012, 118 (18) :4444-4451

← 1 2 3 →